A Comparison of the Efficacy of 5 mg Olanzapine and Aprepitant in the Prevention of Multiple-Day Cisplatin Chemotherapy-Induced Nausea and Vomiting

Table 2

Baseline characteristics of patients in two groups (n (%)).

Characteristics	Olanzapine group (n = 104)	Aprepitant group (n = 106)
Age (years)	59.26 ± 8.865	60.01 ± 10.358	0.574
≥55	79 (75.96)	78 (73.58)	0.692
Gender			0.755
Male	64 (61.54)	63 (59.43)
Female	40(38.46)	43(40.57)
Smoking index			0.474
No smoking	39 (37.50)	47 (44.34)
0∼400	13 (12.50)	9 (8.49)
≥400	52 (50.00)	50 (47.17)
Alcohol use			0.725
No consumption	48 (46.15)	50 (47.17)
<4 drinks per week	38 (36.54)	34 (32.08)
≥4drinks per week	18 (17.31)	22 (20.75)
History of female pregnancy vomiting	13 (32.5)	11 (25.58)	0.487
History of motion sickness	17 (16.35)	21 (19.81)	0.514
Chemotherapy cycle			0.232
First cycle	27 (25.96)	37 (34.90)
Second cycle	30 (28.845)	23 (21.70)
Third cycle	17 (16.35)	23 (21.70)
Fourth cycle	30 (28.845)	23 (21.70)
Type of malignancies			0.755
Lung cancer	40 (38.46)	43 (40.57)
Others	64 (61.54)	63 (59.43)